Hashmi Atif Ali, Mahboob Raeesa, Khan Saadia Mehmood, Irfan Muhammad, Nisar Mariam, Iftikhar Narisa, Siddiqui Maham, Faridi Naveen, Khan Amir, Edhi Muhammad Muzzammil
Department of Histopathology, Liaquat National Hospital and Medical College, Karachi, Pakistan.
Department of Medicine, Kandahar University, Kandahar, Afghanistan.
BMC Res Notes. 2018 Aug 13;11(1):574. doi: 10.1186/s13104-018-3677-y.
Her2neu receptor is proto-oncogene which can be over-expressed in both luminal and non-luminal breast cancers. In the present study, we aimed to compare the prognostic and predictive factors like tumor grade, T-stage, N-stage and ki67 index in Her2neu intrinsic breast cancer subtype with Her2neu over-expressed luminal breast cancers.
801 (41%) cases were Her2neu positive; out of which, 418 cases (52.2%) showed ER positivity and thus were classified as Her2neu positive luminal cancers whereas 383 cases (47.8%) were ER and PR negative and therefore were labeled as intrinsic Her2neu subtype (non-luminal). Her2neu positive (non-luminal) cancers were significantly associated with higher grades and Ki67 proliferative index compared to Her2neu positive luminal cancers. On the other no significant association was noted in T-stage and N-stage. We found a high frequency of her2neu positivity in our studied population of breast cancer. Moreover, association of her2neu positive (non-luminal) breast cancers with higher grade and ki67 index indicates a predictive value of ER/PR positivity in her2neu positive breast cancers. On the other hand, lack of association with respect to T and N stage, signifies no prognostic benefit of ER/PR in her2neu positive breast cancers.
Her2neu受体是一种原癌基因，在管腔型和非管腔型乳腺癌中均可过度表达。在本研究中，我们旨在比较Her2neu内在型乳腺癌亚型与Her2neu过度表达的管腔型乳腺癌的预后和预测因素，如肿瘤分级、T分期、N分期和ki67指数。
801例（41%）为Her2neu阳性；其中，418例（52.2%）雌激素受体（ER）阳性，因此被归类为Her2neu阳性管腔型癌，而383例（47.8%）ER和孕激素受体（PR）阴性，因此被标记为内在型Her2neu亚型（非管腔型）。与Her2neu阳性管腔型癌相比，Her2neu阳性（非管腔型）癌与更高的分级和Ki67增殖指数显著相关。另一方面，在T分期和N分期未发现显著关联。我们在研究的乳腺癌人群中发现Her2neu阳性的频率很高。此外，Her2neu阳性（非管腔型）乳腺癌与更高分级和ki67指数的关联表明ER/PR阳性在Her2neu阳性乳腺癌中的预测价值。另一方面，在T和N分期缺乏关联，表明ER/PR在Her2neu阳性乳腺癌中无预后益处。
